Search clinical trials for: Poziotinib Hydrochloride

Total 7345 results

M.D. Anderson Cancer Center

Withdrawn

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8
Hanmi Pharmaceutical Company Limited

Completed

Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

Metastatic Breast Cancer

Korea, Republic of
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies

Breast Cancer | Colorectal Cancer | Solid Tumor | Glioblastome Multiforme

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Breast Cancer

United States
Samsung Medical Center

Completed

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Metastatic Breast Cancer

Korea, Republic of
Spectrum Pharmaceuticals, Inc

Terminated

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Breast Cancer | NSCLC

United States
Spectrum Pharmaceuticals, Inc

Completed

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Healthy

United States
National OncoVenture
Hanmi Pharmaceutical Company Limited

Terminated

NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma

Adenocarcinoma of Lung Stage IV | Adenocarcinoma of Lung Stage IIIB

Korea, Republic of
Korean Association for the Study of Targeted Therapy
Chonnam National University Hospital; Kyungpook National University Hospital; Konkuk University Medical Center and other collaborators

Completed

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

HER2 Gene Mutation | Adenocarcinoma Lung Stage IV

Korea, Republic of
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Spectrum Pharmaceuticals, Inc

Terminated

A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib

Solid Tumor

United States
Yonsei University

Unknown

A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)

Inoperable or Recurrent or Metastatic Esophageal Squamous Carcinoma

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Terminated

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

Korea, Republic of, China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Spectrum Pharmaceuticals, Inc

Terminated

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

NSCLC

United States, Canada, Netherlands, Belgium, Israel, Spain, France, Italy
National OncoVenture
Hanmi Pharmaceutical Company Limited

Completed

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors (NSCLC)

Increased Drug Resistance

Korea, Republic of
Avistone Biotechnology Co., Ltd.

Recruiting

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Non-Small-Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Recruiting

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (KUNPENG)

Non-small Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Completed

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Glioma

China
Beijing Pearl Biotechnology Limited Liability Company

Completed

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

Non-Small Cell Lung Cancer

China
Hanmi Pharmaceutical Company Limited
National OncoVenture

Completed

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

HER-2 Positive Advanced Gastric Cancer

Korea, Republic of
Spectrum Pharmaceuticals, Inc

Suspended

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE)

NSCLC

United States
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
City of Hope Medical Center
National Cancer Institute (NCI)

Suspended

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Seoul National University Hospital
Chungnam National University Hospital; Korean Cancer Study Group

Completed

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Head and Neck Neoplasms | HNSCC

Korea, Republic of
Neelesh Sharma MD PhD

Completed

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Breast Cancer

United States
Xijing Hospital of Digestive Diseases

Completed

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

Colorectal Adenomas

China
Xijing Hospital of Digestive Diseases

Completed

Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride

Colorectal Adenomas

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet

Uremic Pruritus

China
Galderma R&D

Completed

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Basal Cell Carcinoma

Australia
Betta Pharmaceuticals Co., Ltd.
Tigermed Consulting Co., Ltd

Completed

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Psoriasis

China
Epygenix

Completed

Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.

Dravet Syndrome

United States
Janssen Research & Development, LLC

Completed

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Sexual Dysfunction, Physiological | Ejaculation

Germany, Spain, Portugal, Finland, Sweden, Austria
Advanz Pharma

Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Atrial Fibrillation
National Cancer Institute (NCI)

Active, not recruiting

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal Large B-Cell Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

United States
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
WPD Pharmaceuticals Sp. z o.o.
Worldwide Clinical Trials

Not yet recruiting

A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas

High Grade Glioma
PhytoHealth Corporation

Completed

Bioavailability, Pharmacokinetics and Safety Evaluation of Phencynonate Hydrochloride in Healthy Volunteers

Healthy

Taiwan
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Terminated

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
National Institute of Allergy and Infectious Diseases...
International Tuberculosis Research Center

Withdrawn

Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs

Refractory Pulmonary Tuberculosis

Korea, Republic of
Mundipharma K.K.

Completed

Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies

Recurrent or Refractory T/NK-cell Malignancies

Japan
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

GW786034 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
BioCryst Pharmaceuticals

Completed

Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
University of Maryland, Baltimore

Suspended

Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride

Aortic Aneurysm, Thoracic

United States

Search clinical trials for: Poziotinib Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations